Ensign Peak Advisors
CNTA

Ensign Peak Advisors’s Centessa Pharmaceuticals CNTA Stock Holding History

Ensign Peak Advisors’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-559,744
Closed -$13.6M – 1698
2025
Q3 		$13.6M Hold
559,744
– – 0.02% 388
2025
Q2 		$7.36M Buy
559,744
+121,611
+28% +$1.54M 0.01% 551
2025
Q1 		$6.3M Buy
438,133
+359,133
+455% +$5.88M 0.01% 577
2024
Q4 		$1.32M Hold
79,000
– – ﹤0.01% 1148
2024
Q3 		$1.26M Buy
+79,000
New +$968K ﹤0.01% 1186
2024
Q2 		– Sell
-125,157
Closed -$1.41M – 1719
2024
Q1 		$1.41M Hold
125,157
– – ﹤0.01% 1098
2023
Q4 		$996K Hold
125,157
– – ﹤0.01% 1383
2023
Q3 		$810K Hold
125,157
– – ﹤0.01% 1355
2023
Q2 		$775K Hold
125,157
– – ﹤0.01% 1451
2023
Q1 		$482K Sell
125,157
-123,071
-50% -$450K ﹤0.01% 1650
2022
Q4 		$770K Hold
248,228
– – ﹤0.01% 1377
2022
Q3 		$998K Buy
248,228
+125,157
+102% +$572K ﹤0.01% 1063
2022
Q2 		$599K Sell
123,071
-193,530
-61% -$1.24M ﹤0.01% 1370
2022
Q1 		$2.84M Sell
316,601
-26,691
-8% -$243K 0.01% 754
2021
Q4 		$3.87M Buy
343,292
+56,888
+20% +$765K 0.01% 742
2021
Q3 		$4.78M Sell
286,404
-63,596
-18% -$1.32M 0.01% 674
2021
Q2 		$7.77M Buy
+350,000
New +$8.23M 0.02% 496

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Ensign Peak Advisors's CNTA Position: Q4 2025 in Review

Ensign Peak Advisors sold out of Centessa Pharmaceuticals (CNTA) in Q4 2025, closing a stake of 559,744 shares — an estimated $13.6M sold.

Ensign Peak Advisors first reported a position in CNTA in Q2 2021 and held it in 17 quarters. The position peaked at $13.6M in Q3 2025. 146 funds tracked by Wall St. Rank hold CNTA as of Q4 2025.

  • Ensign Peak Advisors reported no remaining Centessa Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Ensign Peak Advisors sold 559,744 Centessa Pharmaceuticals shares in Q4 2025, an estimated $13.6M.
  • Ensign Peak Advisors first reported a position in Centessa Pharmaceuticals in Q2 2021 and held it in 17 quarters.
  • Ensign Peak Advisors's Centessa Pharmaceuticals position peaked at $13.6M in Q3 2025.
  • 146 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q4 2025.

Based on Ensign Peak Advisors's 13F filing for Q4 2025, filed 12 Feb 2026.